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’INTRODUCTION
The human genome encodes more than 500 protein kinases
that catalyze the reversible phosphorylation of proteins, a regu-
latory mechanism controlling diverse cellular processes.
1,2 No-
tably, perturbations in protein kinase-mediated signaling path-
ways have been reported in many human diseases including
cancer.
3,4 Protein kinases have thus emerged as promising
candidates for molecular-targeted therapy.
5 A prime example of
this selective therapy is the development of imatinib (Gleevec),
dasatinib and nilotinib as ATP-competitive inhibitors targeting
the BCR-Abl fusion protein in chronic mylogenous leukemia
(CML).
6 9 These successes have demonstrated that protein
kinases can be exploited to treat diseases and have encouraged
eﬀorts to develop inhibitors directed against other protein
kinases implicated in a number of human diseases. In addition
to their therapeutic potential, the development of many novel
protein kinase inhibitors has yielded new opportunities to
evaluate enzyme substrate relationships for protein kinases
and to further elucidate their regulatory participation in biologi-
cal events.
10 14However, tocapitalize on the promise ofprotein
kinase inhibitors for therapy and as tools to elucidate the role(s)
of protein kinases in the regulation of biological processes, it is
imperative that unbiased approaches be developed to evaluate
inhibitor speciﬁcity
15 and to validate that inhibitors are eﬀective
when used in cells or in vivo.
Protein kinase CK2 (collectively referring to two isoforms
designated CK2α and CK2α0 in mammals) is one family of
protein kinases that has attracted attention as potential thera-
peutic targets because of its elevated expression in cancer cells,
and participation in a broad spectrum of biological processes.
16
CK2 is classiﬁed as a protein serine/threonine kinase
17,18 that has
also been shown to phosphorylate tyrosine residues.
19 CK2 regu-
lates multiple cellular processes such as cell cycle progression,
20 22
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ABSTRACT:Proteinkinaseshaveemergedasattractivetargets
for treatment of several diseases prompting large-scale phos-
phoproteomicsstudiestoelucidatetheircellularactionsandthe
design of novel inhibitory compounds. Current limitations
include extensive reliance on consensus predictions to derive
kinase substrate relationships from phosphoproteomics data
and incomplete experimental validation of inhibitors. To over-
come these limitations in the case of protein kinase CK2, we
employed functional proteomics and chemical genetics to
enable identiﬁcation of physiological CK2 substrates and vali-
dation of CK2 inhibitors including TBB and derivatives. By 2D
electrophoresis and mass spectrometry, we identiﬁed the trans-
lational elongation factor EEF1D as a protein exhibiting CK2
inhibitor-dependent decreases in phosphorylation in
32P-labeled HeLa cells. Direct phosphorylation of EEF1D by CK2 was
shown by performing CK2 assays with EEF1D-FLAG from HeLa cells. Dramatic increases in EEF1D phosphorylation following
λ phosphatase treatment and phospho-EEF1D antibody recognizing EEF1D pS162 indicated phosphorylation at the CK2 site in
cells. Furthermore, phosphorylation of EEF1D in the presence of TBB or TBBz is restored using CK2 inhibitor-resistant mutants.
Collectively,ourresultsdemonstratethatEEF1DisabonaﬁdephysiologicalCK2substrateforCK2phosphorylation.Furthermore,
this validation strategy could be adaptable to other protein kinases and readily combined with other phosphoproteomic methods.
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apoptosis,
23 27transcription,
28circadian rhythms,
29and has been
demonstrated to promote tumorigenesis in mouse models.
30
While the understanding of its precise roles in tumorigenesis
remains incomplete, its ever-expanding lists of potential interac-
tion partners
31,32 and substrates are consistent with complex roles
in regulatory signaling networks.
33 Furthermore, large scale phos-
phoproteomic studies that have identiﬁed phosphorylated pro-
teins and phosphorylation sites at unprecedented rates oﬀer the
promiseofrevealingathoroughdescriptionoftheroleofCK2and
other protein kinases in cellular regulation.
34 37 Information
about the substrate speciﬁcity and consensus motifs for individual
protein kinases such as CK2
38,39 has aided the prediction of
possible protein kinase:substrate relationships from these studies.
However, to maximize the beneﬁts that emerge from these large-
scale studies, it is important that complementary unbiased experi-
mental strategies be devised to verify that predicted substrates are
in fact direct substrates of the protein kinase of interest.
The development of cell permeable inhibitors of CK2
10,40
has represented a major advance for the discovery of its sub-
stratesandelucidationofitsrolesincellregulation.Furthermore,
since CK2 appears to be constitutively active,
41,42 it is expected
that CK2 inhibitors could be valuable agents to neutralize the
dramatic increases in CK2 activity that accompany its elevated
expression that is frequently observed in human cancers.
43,44
Since many protein kinase inhibitors, including the majority of
CK2 inhibitors, are ATP-competitive inhibitors, there is a clear
need for methods that evaluate their speciﬁcity and the potential
for oﬀ-target eﬀects involving other members of the protein ki-
nase family or other ATP-binding proteins that are abundant in
human cells.
15,45 For example the CK2 catalytic site has unique
features that can be exploited in the design of speciﬁc inhibitors
and in devising strategies to evaluate the speciﬁcity of these
inhibitors. Notably, CK2 is one of the few protein kinases with
the abilitytoutilizeGTP as a substrate
46 and the catalytic pocket
that binds ATP/GTP is somewhat more compact than in other
kinases because of the presence of bulky hydrophobic resi-
dues.
13,47,48 Mutation of these residues in the catalytic site of
CK2α (V66A and I174A) or CK2α0 (V67A and I175A) renders
the kinase less sensitive to the CK2 inhibitor TBB and its deri-
vates.
13,40,49 With the objective of devising a systematic strategy
to identify bona ﬁde substrates of CK2 and with the expectation
that substrates could be used as indicators to validate inhibition
ofCK2incells,wehavecoupledafunctionalproteomicsstrategy
with chemical genetics. We employed two-dimensional electro-
phoresis to identify proteins exhibiting diminished phosphoryla-
tion in cells treated with CK2 inhibitors based on its capacity to
fractionate thousands of individual protein variants, including
separation of diﬀerent phosphorylated forms of individual pro-
teins, and its demonstrated ability to identify substrates for
protein kinases such as MAP kinase.
50 To extend these studies,
we generated inhibitor-resistant mutants of CK2
15 to evaluate
whether the identiﬁed proteins are indeed direct substrates for
CK2. Utilizing these strategies, we identiﬁed EEF1D, a transla-
tional elongation factor implicated as a potential prognostic
indicator in cancer (including medulloblastoma
51 and esopha-
geal carcinoma
52)a sabona ﬁde cellular target of CK2. Given its
potential prognostic value, its ubiquitous expression and abun-
dant nature, our results suggest that EEF1D may be a viable
markerforCK2inhibition.Furthermore, theunbiasedvalidation
strategies utilizing functional proteomics and chemical genetic
methods that we have employed can be readily adapted to
identify and validate bona ﬁde substrates of other kinases.
’EXPERIMENTAL SECTION
Cell Culture and CK2 Inhibitors
The HeLa (Tet-Oﬀ, Clontech) cells used in all experiments
wereculturedinDulbecco’sModiﬁedEagle’smedium(DMEM)
supplemented with 10% fetal bovine serum (FBS), 100 μg/mL
streptomycin and 100 units/mL penicillin (Invitrogen) at 37 C
with5%CO2in10or15cmdishes(Falcon).TheCK2inhibitors
were obtained from commercial suppliers as follows: 2-dimethy-
lamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) was pur-
chasedfromCalbiochem,4,5,6,7-tetrabromobenzotriazole(TBB)
and 4,5,6,7-tetrabromobenzimidazole (TBBz) were from Sigma.
Dimethylsulfoxide(DMSO,Caledon) wasusedassolventforthe
inhibitors in all experiments.
32P Labeling and 2D Gel Analysis
HeLa cells (plated at 10
6 cells per 10 cm dish) were grown for
48 h to approximately 80% conﬂuency in regular DMEM media.
In preparation for biosynthetic labeling, the culture media was
replaced with phosphate-free DMEM (Chemicon) supplemen-
ted with dialyzed 10% FBS, 100 μg/mL streptomycin and 100
units/ml penicillin (Invitrogen) just prior to
32P labeling. Bio-
syntheticlabelingwasachievedbyadding800μCi
32P-orthopho-
sphateinthepresenceorabsenceof25μMDMATorTBBz.For
untreated controls, DMSO was used in equal volumes as in the
inhibitor treatments. After 12 h of
32P orthophosphate labeling,
themediawasremovedandthecellswerewashedtwicewithcold
PBS on ice. The cells were lifted from the dish with PBS con-
taining 5 mM EDTA and the cellular proteins were extracted
with Trizol and separated with two-dimensional (2D) electro-
phoresis using pI 4 7 NL strips (GE Healthcare) for the ﬁrst
dimension (equal cpm of
32P was loaded for each sample). Fol-
lowingSDS-PAGEfortheseconddimension,gelsweredriedand
32P incorporation was detected with autoradiography. The auto-
radiograph images were scanned on an Epson 4990 ﬂatbed
scanner at 16-bit Grayscale and quantiﬁed with ImageQuant
Version 5.2 software (Molecular Dynamics).
32P incorporation
diﬀerences were quantiﬁed by calculating volume ratios of the
corresponding areas from 2D images of 25 μM TBBz, 25 μM
DMAT or DMSO-treated samples. Proteins from nonradioac-
tive experiments, processed with identical conditions as the
32P-labeled samples, were stained with Pro-Q Diamond phos-
phoprotein gel stain (Invitrogen) and then with SYPRO Ruby
stain (Invitrogen). Spots in the 2D gels showing signiﬁcant
inhibitor-dependent decreases in
32P incorporation and Pro-Q
Diamond staining were isolated from nonradioactive gels using
an Ettan Spot Picker (GE Healthcare) and processed further for
analysis by mass spectrometry as described below.
SamplePreparationandIdentificationwithMassSpectrometry
Excised gel pieces were processed using a MASSPrep Auto-
mated Digestor (Waters/Micromass) in our Functional Proteo-
micsFacility(http://www.biochem.uwo.ca/wits/fpf/index.html).
Brieﬂy, the gel pieces were destained using 50 mM ammonium
bicarbonate and 50% Acetonitrile (ACN), the proteins were
reducedin10mMDL-Dithiothreitol(DTT),thenalkylatedusing
55 mM iodoacetamide (IAA) and subjected to in-gel digestion
with Trypsin. Following digestion, peptides were extracted using
1% formic acid and 2% ACN and lyophilized. The lyophilized
peptideswereresuspendedin10%ACNand0.1% Triﬂuoroacetic
acid (TFA) and mixed at a 1:1 ratio (v/v) with α-cyano-4-
hydroxycinnamic acid (CHCA) matrix that was prepared using
5 mg/mLin6mMammonium phosphatemonobasic,50%ACN,4889 dx.doi.org/10.1021/pr2008994 |J. Proteome Res. 2011, 10, 4887–4901
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0.1% TFA. Samples (0.7 μL) were spotted on MALDI plates and
analyzed on a 4700 Proteomics Analyzer (Applied Biosystems,
Foster City, CA) by MALDI-TOF or MALDI-TOF/TOF. The
data were acquired and processed using 4000 Series Explorer and
DataExplorer(bothfromAppliedBiosystems).Themassspectro-
meterisequippedwitha355nmNd:YAGlaserwithalaserrateof
200 Hz and was run in a reﬂectron positive ion mode collecting
a sum of 1000 (MS) or 2000 (MS/MS) laser shots for each mass
spectrum. Calibration was performed with a mass tolerance of
50 ppm. Masses obtained for each sample were submitted to the
MASCOT search engine for peptide mass ﬁngerprint identiﬁca-
tion (http://www.matrixscience.com/cgi) using the SwissProt
database of Homo sapiens with carbamidomethyl (C) ﬁxed and
oxidation (M) plus phosphorylation (ST) variable modiﬁcation
and a peptide tolerance of 15 35 ppm not allowing any missed
cleavages. Identiﬁed proteins were subsequently examined using
existing phosphorylation databases PhosphoSitePlus (www.
phosphosite.org), Phosida (www.phosida.de),
53 PhosphoELM
(phospho.elm.eu.org) and by literature search to determine if
they were previously identiﬁed as phosphorylated proteins in
human cells.
Plasmid Construction and Transfection
The elongation factor 1-delta (designated as EEF1D) cDNA
clone was purchased from American Type Culture Collection.
ToincorporateaFLAGepitopetagateitheritsN-orC-terminus,
the 846 bp EEF1D cDNA encoding the 281 amino acid 31 kDa
EEF1D transcript variant 2 (gi|25453472) was PCR ampliﬁed
with the following primers: N-terminal (FLAG-EEF1D) (Forward:
50-gctaagcttatggactacaaagacgatgacgacaagatggctacaaacttccta-30,
Reverse:50-tgcgaattctcagatcttgttgaaagc-30)orC-terminal(EEF1D-
FLAG) (Forward primer: 50-gctggtaccatggctacaaacttccta-30,
Reverse primer: 50-tgcgaattctcacttgtcgtcatcgtctttgtagtccatgatct-
tgttgaaagc-30).AmpliﬁcationproductswereclonedintopcDNA3.1+
expression vector (Invitrogen) with HindIII/EcoRI or KpnI/
EcoRI cloning sites for FLAG-EEF1D or EEF1D-FLAG, respec-
tively. The nonphosphorylatable S162A (Forward primer: 50-
tgacattgacctgtttggcgctgacaatgaggaggaggac-30, Reverse: 50-gtcctc-
ctcctcattgtcagcgccaaacaggtcaatgtca-30) or phopshomimic S162D
(Forward primer: 50-tgacattgacctgtttggcgatgacaatgaggaggaggac-
30, Reverse: 50-gtcctcctcctcattgtcatcgccaaacaggtcaatgtca-30)m u -
tants of FLAG tagged EEF1D were generated following Quik-
Change Site-Directed Mutagenesis (Stratagene, San Diego, CA).
The plasmids were propagated in DH5α bacterial cells, isolated
with standard methods
54 and veriﬁed by sequencing. In the CK2
siRNA experiments, the individual subunits of CK2 or scambled
control (Dharmacon SMART pools) were transfected at 200nM
ﬁnal concentration for 96 h following the manufacturer’s recom-
mendations. In cell rescue experiments HA tagged form at
C-terminus of wild type (pRc/CMV-CK2α-HA) or inhibitor
resistantformofCK2α(pRc/CMV-CK2α(V66A/I174A)-HA)
15
with N-terminal MYC tagged wild type CK2β (pRc/CMV-
Myc-CK2β)
55 were used.
HeLa cells were transfected at approximately 60% conﬂuency
in 10 cm tissue culture dishes using PEI reagent (Linear, MW
25000,Polysciences,Inc.)inmostexperiments.Lipofectamine2000
(Invitorgen) was used for CK2 siRNA and experiments with
inhibitor-resistant CK2 constructs. For PEI transfections,
56 a
constructencodingEnhancedGreenFluorescentProtein(EGFP)
tomonitortransfectioneﬃciency(1μg)andeitherFLAG-EEF1D
or EEF1D-FLAG pDNA (5 μg) in 440 μL of 150 mM ﬁlter
sterilized NaCl were mixed with 60 μL of PEI (1 mg/mL, in ﬁlter
sterilized 10 mM pH5.5 MES). The pDNA-PEI mixtures were
vortexed for 10 s, incubated for 10 min at room temperature and
then added to the culture media with cells in the plates. In trans-
fections withLipofectamine2000 manufacturer recommendations
were followed using 5 μL of Lipofectamine2000 per 10 cm plate
with 6 mL media. Following transfection, cells were harvested at
the times indicated.
Antibodies, Immunoblotting and Other Reagents
Western blotting
57 was performed using EEF1D antibody
(Novus), FLAG M2Monoclonal Antibody (Sigma) and Anti-β-
lactoglobulin (CedarLane) primary antibodies at 1:1000 dilution
in LiCor Blocking Buﬀer:PBS containing 0.1% Tween 20 (1:1).
The phospho-EEF1D antibody was raised against CDIDLFGpSD-
NEEEDK phospho-peptide recognizing CK2 phosphorylation at
theEEF1DpS162site.Antibodyproductionfrompeptidesynthesis
to aﬃnity puriﬁcation was completed at YenZym Antibodies, LLC,
San Francisco, CA following their proprietary company protocols.
Western blotting with phospho-EEF1D polyclonal antibody was
doneat1:20000dilutionsin1%BSA/TBST.EndogenousCK2α,
CK2α0 or CK2β were immunoblotted with polyclonal antibodies
using previously established protocols.
15,58,59 For the HA- or
MYC-tagged form of CK2 detection monoclonal anti-HA 3F10
(BabCO, Berkley, CA) or anti-MYC 9E10 antibodies were used
as described.
60 For loading controls, anti-Glyceraldehyde-3-
Phosphate Dehydrogenase (GAPDH), clone 6C5 (Millipore)
in 3%BSA/PBST was used at a 1:1000 dilution. Secondary
Infrared IRDye-labeled antibodies (LiCor) (1:10000 dilution
in PBS containing 1% BSA and 0.1% Tween 20) were visualized
on the LiCor Odyssey Infrared Imaging System and evaluated
using Odyssey V3.0 software. All 2D electrophoresis reagents
and Protein G Sepharose used for immuno-precipitation were
from GE Amersham.
Purification of Recombinant CK2
Aninhibitor resistant mutantofGST-CK2α(ie.V66A/I174A)
designated CK2αR
15 was generated with the Quikchange Muta-
genesis Kit (Stratagene). Wild type GST-CK2α or GST-CK2αR
were expressed in bacteria and puriﬁed according to previously
established protocols.
61 To obtain the wild type (holo-CK2WT)
or the inhibitor resistant form of holo-CK2 (holo-CK2R), the
bacterial pellets from GST-CK2α-expressing or GST-CK2αR-
expressing bacteria were mixed with twice the volume of pellet
from bacteriaexpressing His-taggedCK2βbacterialpelletand the
enzymes were puriﬁed by Glutathione aﬃnity chromatography as
for GST-CK2α or GST-CK2αR. The protein concentrations of
the puriﬁed enzymes were determined by BioRad Protein Assay.
Puriﬁed enzymes were also separated by 10% SDS-PAGE and
stained with GelcodeBlue (Thermo) protein stain to conﬁrm the
monomeric or holo-enzyme form of CK2.
62
In vitro Phosphorylation Assays
The CK2 substrate peptide RRRDDDSDDD (100 μM) was
usedtomeasure theactivity of the puriﬁedenzymes. Each kinase
reaction (40 μL) contained 50 mM Tris pH 7.5, 100 mM NaCl,
12mMMgCl2,0.01mMATPsupplementedwith1.6μCiγ-
32P-
ATP per reaction. Prior to the phosphorylation reactions, the
inhibitors at 25 μM concentration were preincubated on ice
with CK2 for 18 min and the enzyme:inhibitor was diluted into
the kinase reaction to achieve a 5 μM ﬁnal concentration of the
inhibitor. Kinase reactions (10 min at 37 C) were performed
according to established protocols.
10,63,64 32P incorporation,
residual kinase activity was calculated for each experiment and4890 dx.doi.org/10.1021/pr2008994 |J. Proteome Res. 2011, 10, 4887–4901
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therepresentativeresultofthetwoexperimentswasdisplayedon
the ﬁnal ﬁgures.
For immuno-kinase assays, EEF1D-FLAG or the mutant
forms of S162A and S162D were immuno-precipitated from
500 μg of transfected HeLa lysate with 2.5 μg of FLAG M2
antibody following the protocol outlined previously
19 and then
usedforsubstrateinkinasereactions.Whereindicated,immuno-
precipitated EEF1D-FLAG and mutants were preincubated with
λ-phosphatase (New England Biolabs). Kinase reactions were
terminated by the addition of 50 μL2   Laemmli sample buﬀer
and 25% of the reaction was separated on 10% SDS-PAGE gels.
Each reaction was separated twice on SDS-PAGE gels (technical
replicate) and the experiment was repeated twice. All phosphor-
ylation reactions were exposed to PhosphorImager screens,
scanned on Storm 820 scanner (GE Healthcare) and quantiﬁed
with ImageQuant Version 5.2 software. One PhosphorImager
scan of the two experiments was displayed on the ﬁgures.
Alternatively, the CK2 phosphorylation dependent change of
EEF1D-FLAGwasvisualizedwithanonradioactivemethod.The
immunoprecipitated EEF1D-FLAG were treated with λ-phos-
phataseand/orsubjectedtokinasereactionsasindicatedandthe
reactions were separated with 2D electrophoresis followed by
immuno-blotting with FLAG M2 antibody. The immuno-blots
were scanned on the LiCor Odyssey System and the signal
intensity change of the 2D proﬁle was analyzed by Odyssey V3.0
software (LiCor).
Analysis of Phosphorylation in Cells Expressing Inhibitor-
Resistant CK2 Constructs
For rescue experiments with inhibitor-resistant CK2, HeLa
cells were transfected in 15 cm size dishes using DMEM media
without FBS or antibiotic at 80% conﬂuency. Equal amount
of wild type pRc/CMV-CK2α-HA and pRc/CMV-Myc-CK2β
(10μgeach)plus5μgofEGFPtomonitortransfectioneﬃciency,
or inhibitor resistant pRc/CMV-CK2α(V66A/I174A)-HA and
pRc/CMV-Myc-CK2β (10 μg each) plus 5 μg of EGFP plasmid
DNA were transfected with 12.5 μL of Lipofectamine2000
following manufacturer’s recommendations. After 12 h incuba-
tion, themedia was replacedwithDMEM/0.1%FBS/100μg/mL
streptomycin and 100 units/mL penicillin and cells incubated for
an additional 6 h. The cells were then transfected again with
EEF1D-FLAG (20 μg) and EGFP (5 μg). Seven hours after the
secondtransfectionallcellswereliftedwithPBScontaining5mM
EDTA, pooled together into a single 50 mL tube, and then
distributed equally into six of 10 cm plates containing 10 mL of
DMEM/10% FBS/100 μg/mL streptomycin and 100 units/mL
penicillin. One fraction of the cells were pelleted (100 xg, 4 C),
and were frozen at  80 C to be used as 0 h control for EEF1D-
FLAG protein expression level at the time of kinase inhibitor
treatment. The cells in 10 cm plates were treated with CK2
inhibitors TBB (25 or 15 μM) or TBBz (15 or 8 μM). Dimethyl
sulfoxide (DMSO) was added to control cells (DMSO cont.) or
cells were kept without any treatment (12 h Untrd.). Following
12hofincubation,allcellswereharvestedandwashedfourtimes
with ice cold PBS on ice prior to lysis in Tris Lysis Buﬀer (TLB,
50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% Deoxy-
cholic Acid, 29.4 μg/mL Aprotinin, 1 mM PMSF, 20 μg/mL
Leupeptin, 7 μg/mL Pepstatin A, 1 μM Okadaic acid, 1 μM
Microcystin, 1 mM Sodium orthovanadate, 5 mM NaF). Cells
from the 0 h treatment were lysed in the same buﬀer without
phosphatase inhibitors. Cells were sonicated for 3   5 s on ice
andthenkeptoniceforanadditional30mintoachievecomplete
lysis.Lysateswerecleared bycentrifugation(2330 g,4C)and
protein concentrations were measured with BCA Protein Assay
Kit (Pierce) using BSA as standard.
EEF1D-FLAG was immuno-precipitated according to the
protocol described above from 400 μg of lysate per treatment
with 2.5 μg of FLAG M2 antibody. For phospho-EEF1D anti-
bodyimmuno-blotting,onereactionoftheimmuno-precipitated
EEF1D-FLAGproteinof0hcontrolwastreatedwithλ-phosphatase
andthen20%ofeachreactionwasseparatedon10%SDS-PAGE.
For detection of endogenous or transfected CK2, 12.5 μgo f
lysate was separated on 10% SDS-PAGE gels. Proteins were
transferred to Immobilon-FL PVDF membrane (Millipore) and
immuno-blotted with antibodies indicated in the ﬁgures and
following the protocol described above.
2D Electrophoresis to Monitor Phosphorylation Profiles of
EEF1D
Proteins were immuno-precipitated prior to 2D electrophor-
esis and 2D proﬁles of EEF1D-FLAG examined with or without
subsequent λ-phosphatase treatments. Brieﬂy, transfected HeLa
cells were harvested with Tris Lysis Buﬀer (TLB, 50 mM Tris
pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% Deoxycholic Acid,
29.4 μg/mL Aprotinin, 1 mM PMSF, 20 μg/mL Leupeptin,
7 μg/mL Pepstatin A) and subjected to immuno-precipitation
with FLAG M2 antibody (2.5 μg) using Protein G-Sepharose at
4 C. Immune-complexes were collected by centrifugation and
washed four times with NP-40 buﬀer (50 mM Tris pH 7.5,
150 mM NaCl, 1% NP-40, 29.4 μg/mL Aprotinin, 1 mM PMSF,
20 μg/mL Leupeptin, 7 μg/mL Pepstatin A) followed by two
washes with the same buﬀer lacking NP-40. After treatment with
or without λ-phosphatase, the reactions were washed once
(50 mM Tris pH 7.5, 150 mM NaCl, 29.4 μg/mL Aprotinin,
1 mM PMSF, 20 μg/mL Leupeptin, 7 μg/mL Pepstatin A, 1 μM
Okadaic acid, 1 μM Microcystin, 1 mM Sodium orthovanadate)
and then the buﬀer was removed completely. The proteins were
eluted using 80 μL of 2D lysis buﬀer (8 M Urea, 2% CHAPS,
1mMBenzamidine,25μg/mLLeupeptin,20μg/mLPepstatinA,
20 μg/mL Aprotinin, 1 μM Okadaic acid, 1 μM Microcystin,
1 mM Sodium orthovanadate, 0.5% Ampholyte and 40 mM
DTT) with constant rotation at 4 C for 15 min. β-lactoglobulin
(100 ng, Sigma) was added to 50 μL of each sample as an iso-
electricfocusingmarkerpriortosampleapplicationto4 7NL2D
strips for theﬁrst dimensionseparation. Followingseconddimen-
sionalseparationon10%SDS-PAGE,proteinsweretransferredto
Immobilon-FL PVDF membrane (Millipore) and immuno-
blotted with FLAG-M2 and β-lactoglobulin antibodies.
In CK2 inhibitor experiments, when GFP expression was ﬁrst
detectable by ﬂuorescence microscopy after transfection, the
cells were treated with CK2 inhibitors (25 μM) or an equivalent
volume of DMSO for 12 h. After treatment, cells were washed
withicecoldPBS(4 )oniceandharvestedwith2Dlysisbuﬀer.
Cell lysates were cleared by centrifugation (2330  g,4C) to
remove insoluble materials and the protein concentration was
measured with the BioRad Protein Assay (BioRad) using BSA as
standard.Theproteinswereseparatedby2Delectrophoresisand
then immono-blotted and visualized as described above.
’RESULTS
Development of a Strategy to Identify and Validate Protein
Kinase Substrates
The systematic unbiased strategy that we developed to
identify and validate bona ﬁde substrates for protein kinases is4891 dx.doi.org/10.1021/pr2008994 |J. Proteome Res. 2011, 10, 4887–4901
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outlined in Figure 1. The starting point is the identiﬁcation of
proteinsthat exhibit inhibitor-dependentdecreases inphosphor-
ylation. Since inhibitor-dependent decreases in phosphorylation
couldarisefromdirecteﬀectsontheactivityoftheproteinkinase
targeted by the inhibitor or from indirect eﬀects on downstream
protein kinases within a signaling pathway, an important com-
ponent of the strategy is to demonstrate direct phosphorylation
of the target by the protein kinase under investigation. To per-
formthesestudies,thesubstratecanbeisolatedfrommammalian
cells and evaluated as a direct protein kinase substrate. The
isolatedproteincan alsobetreated withphosphataseprior tothe
protein kinase assay to assess whether the relevant phosphoryla-
tion sites are occupied in cells (i.e., prior treatment with phos-
phatase would enhance the level of phosphorylation observed in
theproteinkinasereaction).Additionally,thephosphorylationof
the substrate in cell by the selected kinase can be demonstrated
by developing phospho-site speciﬁc antibodies recognizing the
predictedphosphorylated residue ontheprotein thatismodiﬁed
by the kinase. The phospho-antibody is a valuable tool to moni-
tor kinase activity dependent change following targeted knock-
down of thekinase bysiRNAorshRNAandevaluate the eﬃcacy
of kinase inhibitors. As a companion to these studies, inhibitor-
resistant mutants of the protein kinase can be used to overcome
(i.e., rescue) the eﬀects of the inhibitors.
While there are now a number of proteomics strategies that
enablethecomparativeanalysisofproteinabundanceorextentof
phosphorylation, many of these methods require access to
dedicated mass spectrometers and extensive analysis of large
data sets. By comparison, despite suggested limitations such as
limited dynamic range and relatively low sample throughput, 2D
gels that are readily available and routinely performed in many
laboratories,havethecapacitytofractionateanddistinguishindi-
vidual protein variants on the basis of covalent modiﬁcations
such as phosphorylation. Accordingly, since our goals were pri-
marilytodeviseavalidationstrategyfortheidentiﬁcationofdirect
substratesforproteinkinases,thelimitationsof2Dgelswouldnot
be of consequence especially when using
32P incorporation to
directlyidentifyproteinsthatarephosphorylatedincells.Toapply
thisstrategytotheidentiﬁcationofsubstratesforCK2,
32Plabeled
HeLa cells were treated with CK2 inhibitors and proteins were
separatedby2Dgelelectrophoresis(Figure2).Proteinsexhibiting
inhibitor-dependentdecreasesin
32Pincorporationwereidentiﬁed
Figure1. Schematicrepresentationoftheunbiasedexperimentalstrategytoidentifyandvalidatebonaﬁdekinasesubstratesusingfunctionalproteomics
methods in combination with chemical genetics. The main components of the validation strategy include: (1) identiﬁcation of proteins exhibiting
inhibitor-dependent changesinphosphorylation, (2)validatinginhibitionofphosphorylation withselectiveknockdownofthekinase,(3)development
of a phospho-speciﬁc antibody to speciﬁcally detect phosphorylation, and (4) performing rescue experiments where inhibitor-resistant kinase is
employed to overcome inhibitor eﬀects on phosphorylation.4892 dx.doi.org/10.1021/pr2008994 |J. Proteome Res. 2011, 10, 4887–4901
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bymassspectrometry.Identiﬁedproteinsweresearchedinexisting
phosphorylation databases (including Phosphosite, Phosida,
PhosphoELM) and in the literature to determine if there was
anypriorevidenceofphosphorylation.Threeproteins,exhibiting
a CK2 inhibitor-dependent decrease in phosphorylation, were
identiﬁed by mass spectrometry from areas circled in white on
Figure 2. These proteins identiﬁed by MALDI-TOF, had also
been listed as phosphoproteins by previous phosphoproteomics
studies,andwereidentiﬁedaselongationfactor1-delta(UniProt
name: EEF1D_HUMAN, area “a” Figure 2), F-actin-capping
proteinsubunitalpha-1(UniProtname:CAZA1_HUMAN,area
“b” Figure 2) and nucleoside diphosphate kinase A (UniProt
name: NDKA_HUMAN, area “c” Figure 2). Mass spectra and
peptide sequences are listed in Figure S3 (Supporting Informa-
tion). Out of the three candidate substrates, we selected
EEF1D for testing our validation strategy on the bases that
EEF1D was listed in multiple phosphorylation databases
(Table S2, Supporting Information), conﬁrming that it was
phosphorylated in cells at sites matching the CK2 consensus
phosphorylation sequence (S/TXXD/E/pS/pY). Notably, re-
combinant EEF1D had also been shown to be a substrate for
puriﬁedCK2invitro.However,likethevastmajorityofpredicted
protein kinase substrates, there were no studies performed to
manipulateitsphosphorylationincellsnortodeterminewhether
it is a bona ﬁde physiological substrate for CK2.
Validation of EEF1D as a Direct CK2 Substrate
TheEEF1Dproteinsequencealignmentclearlydemonstrated
that the CK2 site was highly conserved among diﬀerent species
(Table S1, Supporting Information). These ﬁndings provided
additionalassurancethatEEF1Dwasasuitablecandidatetocarry
out our validation strategy. Accordingly, EEF1D was FLAG
tagged on the N- and C-termini and expressed in HeLa cells.
Theexpressedproteinwasimmuno-precipitatedusingtheFLAG
Figure2. Identiﬁcationofproteinswithinhibitor-dependentdecreasesin
32Plabeling.The
32PlabeledHeLacellsweretreatedwithDMSO(AandD),
25 μM TBBz (B) or 25 μM DMAT (E) for 12 h. Proteins were separated by 2D electrophoresis and
32P incorporation was detected with
autoradiography. ImageQuant quantiﬁcation (C, F) of the areas circled in white (a,b,c) showed signiﬁcant reduction in
32P incorporation. The
diﬀerencesin
32PincorporationwerequantiﬁedasdescribedintheExperimentalSection.Circledspotswereexcisedfromunlabeledgelsandanalyzedby
mass spectrometry to identify candidate substrates for CK2. Images are representative of duplicate experiments.4893 dx.doi.org/10.1021/pr2008994 |J. Proteome Res. 2011, 10, 4887–4901
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M2 antibody and immuno-blotted with both FLAG M2 and
EEF1Dantibodies(Figure3A).TheC-terminallytaggedformof
EEF1D(EEF1D-FLAG)showedhigherexpressioninHeLacells
(Figure 3A) and was selected for further experiments. Impor-
tantly, EEF1D-FLAG expressed in HeLa cells was functional in
mammalian cells as indicated by its complex formation with
endogenous proteins. In this respect, EEF1D-FLAG formed
complexeswith three endogenousmembersoftheEEF1complex
thatcouldbeisolatedbycoimmuno-precipitation(Figure3B)and
identiﬁed by MALDI-TOF analysis as elongation factor 1-alpha
(UniProt name: EEF1A_HUMAN), elongation factor 1-beta
(UniProtname:EEF1B_HUMAN) andelongationfactor1-gamma
(UniProt name: EEF1G_HUMAN). Mass spectra and other
MALDI-TOF identiﬁcation parameters are listed in Figure S4
(Supporting Information). Immuno-kinase assays with the wild
type catalytic CK2α subunit (designated CK2αWT) in vitro
demonstrated that both EEF1D-FLAG and the endogenous
EEF1B were substrates of CK2 (Figure 3C). Furthermore, prior
treatment of immunoprecipitates with λ-phosphatase led to a
dramatic increase in phosphorylation of both proteins by CK2
(Figure 3C). The enhanced phosphorylation following phospha-
tase treatment clearly indicates substantial occupancy of the CK2
phosphorylation sites of the candidate substrates in human cells.
To further examine the phosphorylation proﬁles of EEF1D,
we performed 2D electrophoresis (Figure S1 andS2, Supporting
Information). Initially, the 2D proﬁle of EEF1D-FLAG was
evaluated ( λ-phosphatase treatment revealing a proﬁle shift
toward the less acidic region following phosphatase treatment
(Figure S1, Supporting Information). Visualization of the proﬁle
shiftcouldbefurtherenhancedwiththeuseofbeta-lactoglobulin
as an isoelectric-focusing marker. The shift toward the less acidic
region in the 2D proﬁle could also be observed expressing
EEF1D-FLAG in HeLa cells treated with CK2 inhibitor at dif-
ferent times or concentrations (Figure S2A, Supporting Informa-
tion).TheCK2-dependent2Dproﬁlechangewasalsoconﬁrmedby
separatingtheimmune-complexkinaseassays(FigureS2B,Support-
ing Information). In order to quantify changes in the 2D proﬁle, we
compared intensity changes after CK2 phosphorylation and CK2
inhibitor treatment. We determined that changes in spot numbers
5and6werethemostprominentandreﬂectedtheactivityofCK2in
the assays (Figure S2B, Supporting Information). Collectively, these
results suggested that phosphorylation of EEF1D was responsive to
CK2 inhibitors in HeLa cells.
While 2D electrophoresis suggested that the phosphorylation
proﬁle of EEF1D was aﬀected by CK2 inhibition, these analyses
did not provide a direct assessment of speciﬁc site(s) of phos-
phorylation. Therefore, in order to monitor CK2 activity depen-
dent phosphorylation on EEF1D we developed a phospho-
EEF1D antibody against a EEF1D phospho-peptide shown in
Figure 4A (top sequence) that corresponds to a predicted CK2
site that is present in both Phosida and PhosphoELM (Table S2,
Supporting Information). Using this phospho-EEF1D antibody,
the immuno-blots in Figure 4B showed two distinct groups of
bands,correspondingtoEEF1DandEEF1BonFigure3B.More-
over, our results indicated that our phospho-EEF1D antibody
could recognize EEF1D and EEF1B from HeLa cell lysates only
when lysates were not previously treated by λ-phosphatase. The
alignment of EEF1D and EEF1B protein sequences demon-
strated that only one amino acid diﬀerence was found between
thetwoproteinsneartherecognitionsiteofthephospho-EEF1D
antibody. The pSer in the immunizing peptide corresponds to
pS162 on EEF1D and pS106 on EEF1B (Figure 4A). In peptide
Figure 3. Investigation of EEF1D as a candidate CK2 substrate. (A) Schematic representation of EEF1D with N- (FLAG-EEF1D) or C- (EEF1D-
FLAG)terminalFLAGtag.OverlappingsignalsofFLAGM2monoclonalandEEF1DpolyclonalantibodiesidentiﬁedtheFLAGtaggedformofEEF1D
after the proteinswere immuno-precipitated withFLAG M2antibody. Nontransfected HeLacellslysate was usedascontrol(NTcontrol) (B)EEF1D-
FLAG expressed in HeLa cells coimmuno-precipitated with other three members of the EEF1 protein complex that were identiﬁed by MALDI TOF.
(C)PhosphorylationofEEF1D-FLAGandelongationfactor1-beta(EEF1B)byCK2αWT.
32P-ATPincorporationintheinvitrokinaseassaysonboth
proteinsgreatlyincreasedafterλ-phosphatasetreatmentindicatingthatbothproteinswerephosphorylatedinhumancells.Resultsarerepresentativeof
two experiments.4894 dx.doi.org/10.1021/pr2008994 |J. Proteome Res. 2011, 10, 4887–4901
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competition assays, the phospho-EEF1D signal could be com-
peted out with an excess of phospho-EEF1D peptide and there
was no signal loss with the same molar excess of nonphospho-
EEF1D peptide (Figure 4B). We also tested the CK2 dependent
phosphorylation speciﬁcity of the phospho-EEF1D antibody.
For these studies, we used EEF1D-FLAG as CK2 substrate in
in vitro immuno-kinase CK2 assays. In these assays the antibody
recognized phosphorylation of EEF1D-FLAG by CK2 and on
the coimmuno-precipitated endogenous EEF1B (Figure 4C).
Tofurtherexaminethedependenceofthephosphorylation of
S162of EEF1D on CK2, we performed CK2knockdown studies
(Figure 4D). Treatment with siRNA targeting CK2α resulted in
decreased phosphorylation of EEF1D and EEF1B, as compared
to the level of phosphorylation observed in cells treated with a
control (scrambled) siRNA. These studies further suggest that
EEF1D is a direct substrate of CK2. Furthermore, detection of
endogenous EEF1D with the phospho-speciﬁc S162 antibody
deﬁnitively demonstrates that this residue is phosphorylated in
human cells.
Validation of CK2 Substrates with Inhibitor-resistant CK2
Mutants Using Recombinant Enzymes
Since protein kinase inhibitors are often prone to oﬀ-target
eﬀects,oursubstratevalidationstrategyalsoincorporatedtheuse
of inhibitor resistant mutants of CK2 to evaluate the ability of
these mutants to restore substrate phosphorylation in the pre-
sence of the inhibitor. Inhibitor-resistant variants of CK2α were
prepared both as free catalytic subunits (CK2αR) and as holo-
enzyme complexes comprised of both catalytic and regulatory
CK2 subunits (holo-CK2R). As expected, wild-type CK2 holo-
enzyme (holo-CK2WT) displayed more activity toward the
synthetic CK2 substrate peptide RRRDDDSDDD than did the
Figure 4. Characterization ofaphosphospeciﬁcantibodyrecognizing S162ofEEF1D.(A)EEF1Dpeptidesequence (top)used forphospho-antibody
development. High level of similarity between EEF1D and EEF1B near the CK2 phosphorylation site explains why phospho-EEF1D antibody can
recognizephosphorylationonbothproteins.(B)Peptidecompetitionusingmolarexcess(200 )ofphospho-ornonphospho-peptideonimmunoblots
demonstrates speciﬁcity of phospho-EEF1D antibody. (C) Phosphorylation on EEF1D-FLAG and EEF1B by CK2 is detected by the phospho-EEF1D
antibody. (D) Targeted knock down of CK2α by siRNA (200 nM of Dharmacon SMART pools) for 96 h in HeLa cells results in reduced EEF1D
phosphorylationbyCK2.ThelevelofphosphorylatedEEF1D,endogenousCK2αandCK2α0 weremeasuredwithimmunoblotting.GAPDHwasused
to demonstrate equal gel loading. Results are representative of two independent experiments.4895 dx.doi.org/10.1021/pr2008994 |J. Proteome Res. 2011, 10, 4887–4901
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isolated CK2αWT subunit. A similar observation was made when
comparingholo-CK2RtoCK2αRindicatingthattheabilityofCK2β
to enhance CK2 activity is not compromised by the V66A/I174A
substitutions that are introduced to generate the inhibitor-resistant
forms of CK2. Notably, in these kinase assays, inhibitor-resistant
forms(bothcatalyticCK2αRandholo-CK2R) restoredthesubstrate
phosphorylationinthepresenceoftheinhibitor.Restorationofkinase
activity was more evident after the residual kinase activities of the
reactions were calculated and compared (kinase activity with DMSO
alone=100%,Figure5A).TheseresultsclearlyindicatedthatTBBand
TBBz could both eﬀectively inhibit CK2, and that the inhibitor-
resistantformsofCK2couldrescueactivitytowardapeptidesubstrate
in the presence of the CK2 inhibitors.
As a next step, we proceeded to utilize the inhibitor resistant
CK2 mutants to evaluate their ability to rescue the phosphoryla-
tionofEEF1D-FLAGinthepresenceoftheCK2inhibitors.CK2
kinase assays using EEF1D-FLAG (immuno-precipitated from
HeLa cells and the treated with λ-phosphatase) as substrate
showed multiple phosphorylated bands, most notably the EEF1D
and EEF1B that were previously identiﬁed by mass spectrometry
(FigureS4,SupportingInformation).Intheassaysperformedwith
the holo-enzyme forms of CK2, CK2β autophosphorylation by
CK2α was also evident (Figure 5C). With wild-type forms of
CK2,asigniﬁcantdecreaseinphosphorylationofbothEEF1Dand
EEF1B was visible in the presence of TBB or TBBz. By compar-
ison,whileinhibitor resistant forms doshowa modest decrease in
Figure 5. In vitro phosphorylation of EEF1D using inhibitor resistant forms of CK2. (A) Residual kinase activity, as compared to DMSO control =
100% activity, with wild type (WT) or inhibitor-resistant (R) CK2α or holo-enzyme on RRRDDDSDDD peptide using 5 μM TBB or TBBz. Kinase
activity was restored using the inhibitor-resistant form of CK2. The bars in panel A represent the range of two samples of the reaction in one of two
independent experiments. (B and C) Rescue of kinase activity with the inhibitor resistant CK2 on EEF1D-FLAG, EEF1B and CK2beta (C only) in
in vitro immune-kinase assays.
32P-ATP incorporation was measured on λ-phosphatase treated EEF1D-FLAG that was phosphorylated in immune-kinase
assay by wild type (WT) or inhibitor resistant (R) CK2α or holo-CK2 enzyme. Representative results from two independent experiments are shown.4896 dx.doi.org/10.1021/pr2008994 |J. Proteome Res. 2011, 10, 4887–4901
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kinaseactivity,neitherTBBnorTBBzhaveanappreciableeﬀecton
thephosphorylationofeitherEEF1DorEEF1B(Figure5BandC).
Similar eﬀects are observed with the phosphorylation of CK2β
when using holo-CK2 R. Notably, CK2αWT and holo-CK2WT
activity were higher on EEF1D and EEF1B than the activity
measured with the inhibitor resistant form in the DMSO control
reactions. However, there was no diﬀerence in kinase activity
between the wild type and inhibitor resistant form of holo-CK2
in the autophosphorylation reaction on CK2β (Figure 5B and
C). Collectively, these results indicated that inhibitor-resistant
mutants of CK2 can be employed to ensure that TBB- or TBBz-
dependentdecreasesinphosphorylationdoindeedarisethrough
CK2 inhibition.
Validation of CK2 Substrates by Expressing Inhibitor-
resistant CK2 Mutants in Cells
To further our validation strategy, we expressed wild type or
inhibitor resistant forms of the CK2 in cells. By monitoring CK2
activity with the phospho-EEF1D antibody we observed that
EEF1D-FLAG was immediately phosphorylated by CK2 in cells
afterexpressionasevenaweakbandwasobservedattime0inall
experiments (Figure 6, top panel). Time 0 was deﬁned as the
earliest time point when green ﬂuorescent protein could be
detectedinlivingcellsbyﬂuorescencemicroscopy(typically∼6h
following transfection). At this time point, we did not observe
notable diﬀerences in kinase activity between wild type and
inhibitor resistant forms of CK2 expressed in HeLa cells
(Figure 6, IB:phospho-EEF1D). Furthermore, we did not detect
diﬀerences in expression of endogenous (IB:CK2α/α0/β)o r
transfected (IB:HA 3F10 and MYC 9E10) CK2 comparing
immunoblots with the wild type or inhibitor resistant CK2 in
Figure 6. However, CK2 inhibition for 12 h resulted in a
signiﬁcant decrease in phosphorylation of EEF1D-FLAG and
endogenous EEF1B with TBBz (last 2 lanes of Figure 6; top left
panel)andtoalesserextentwithTBB.Thisdiﬀerenceinpotency
of TBBz over TBB is consistent with our previous ﬁndings.
15
Notably,thesignalintensityofPhospho-EEF1DandEEF1Bwas
partially restored by the expression of inhibitor-resistant CK2
(compare last 2 lanes of right panel and left panel of Figure 6).
Again,theeﬀectwasmoreevidentincellstreatedwithTBBzpre-
sumably because the inhibitory eﬀect of TBBz was more dra-
matic, which made the rescue more readily detectable.
Evaluation of EEF1D WT and S162A or S162D Mutants
TofurtherreinforcetheconclusionthatS162isphosphorylated
in cells, we engineered mutants harboring nonphosphorylatable
and phospho-mimetic substitutions of this residue (Figure 7). In
HeLa cells, S162A and S162D mutants of EEF1D-FLAG were
expressed to similar levels as wild-type EEF1D in multiple experi-
ments (Figure 7). Immuno-blotting with FLAG M2 did not show
diﬀerencesinEEF1D-FLAGwildtypeormutantexpressionlevels
in HeLa cells, however our phospho-EEF1D antibody did only
recognize the wild type form of EEF1D-FLAG (Figure 7A). The
mutants formed complexes with the endogenous EEF1A, EEF1B,
EEF1G and also with EEF1D as shown on the Gelcode Blue
stained gel in Figure 7A. As was expected only the EEF1D-FLAG
WTcouldbephosphorylatedbythecatalyticorholo-formofCK2
as demonstrated by both autoradiography or by immuno-blotting
withourphospho-EEF1Dantibody(Figure7B).Coupledwiththe
observations that CK2 can directly phosphorylate EEF1D, phos-
phatase treatment enhances phosphate incorporation, and that
targeted siRNA knock down of CK2 resulted in decreased CK2
site speciﬁc phosphorylation, these results support the conclusion
that EEF1D is a bona ﬁde physiological substrate of CK2 in
human cells.
’DISCUSSION
The perturbation of cell signaling networks in human diseases
(e.g., cancer) have generated a high level of attention in protein
kinases and fuelled interest in protein kinase inhibitors as tools to
manipulatespeciﬁcsignalingpathwaysandaspotentialtherapeutic
Figure6. Expressionofinhibitor-resistantCK2restoresphosphorylationofEEF1DinthepresenceofCK2inhibitors.HeLacellsweretransfectedwith
wild type CK2 (pRc/CMV-CK2α-HA and pRc/CMV-Myc-CK2β) or an inhibitor resistant form of CK2 (pRc/CMV-CK2α(V66A/I174A)-HA and
pRc/CMV-Myc-CK2β)priortotransfectionagainwithEEF1D-FLAG.Afteranadditional7h,cellsweretreatedwithCK2inhibitorsasindicated.Cells
harvestedattime0(incubatedwithorwithoutλphosphatase asindicated),cellstreated for12hwithDMSOonly(DMSOcont.)orcellsincubatedfor
12 h without treatment (12 h Untrd) were experimental controls. Anti-Flag immunoprecipitates were analyzed by immunoblotting with phospho-
speciﬁc anti-EEF1D antibodies. For better visualization of0 h control bands (run on the same gel), the image intensities were enhanced with the LiCor
Odyssey software andthe imageswere displayedseparated fromthe rest oftheimmunoblot (top panel).Alternatively, celllysates wereimmunoblotted
with a mixture of CK2α and CK2α0 antibodies, with anti-HA antibodies, anti-CK2β antibodies or anti-Myc antibodies as indicated to detect both
endogenous and transfected CK2. Anti-GAPDH was used to conﬁrm equal loading. Results are representative of two independent experiments.4897 dx.doi.org/10.1021/pr2008994 |J. Proteome Res. 2011, 10, 4887–4901
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agents.
3 5 With the objective of comprehensively describing pro-
tein phosphorylation events in cells, a number of global phospho-
proteomic studies have been performed employing mass spectro-
metry and other strategies.
34 37,65 However, to fully capitalize on
the potential of protein kinase inhibitors and the wealth of
information that is emerging from phosphoproteomic studies,
it is necessary to develop systematic and unbiased approaches
for validation of protein kinase inhibitors and protein kinase 
substrate relationships. In this study, we combined the use of 2D
electrophoresis coupled to mass spectrometry
50 together with the
use of protein kinase inhibitors and inhibitor-resistant protein
kinase mutants to identify elongation factor 1-delta (EEF1D) as a
bona ﬁde physiological substrate for CK2.
EEF1D may be an attractive candidate as a biomarker since
elevated levels of EEF1D are associated with transformation,
52
invasiveness
66,67 and poor survival in cancer.
51 Furthermore,
EEF1D has been implicated in the pathogenesis of amyotrophic
lateral sclerosis.
68 EEF1D is one of the members of the EEF1
complex
69 thatcatalyze GDP/GTP exchange on EEF1A in com-
plex with EEF1G and EEF1B subunits (Figure 3C) with the
ability to regulate translation.
70 EEF1D derived from rabbits was
reported to be phosphorylated in vitro by CK2 at Ser162
71 73 a
residue that is highly conserved between species (Table S1,
Supporting Information). Furthermore, phosphoproteomics da-
tabases (Table S2, Supporting Information) and global proteo-
mics studies indicated that EEF1D is indeed phosphorylated in
cells with two residues, namely Ser162 and Thr147 identiﬁed as
sites of phosphorylation upstream to the N-terminus.
34 37,74,75
While these ﬁndings suggest that EEF1D is an attractive candi-
date as a physiological substrate for CK2, there was a lack of
experimentalevidence toconﬁrm that EEF1Dis phosphorylated
directly by CK2 in human cells. Consequently, to build on these
Figure 7. Evaluation ofwild type andmutant forms of EEF1D-FLAG.(A) Wildtype and S162A or S162D forms ofEEF1Dwere transiently expressed
in HeLa cells. Proteins were immuno-precipitated with FLAG M2 antibody from equal amount of cell lysates according to the experimental protocols
and then immuno-blotted or stained by GelcodeBlue as indicated on the ﬁgure. Anti-GAPDH was used to demonstrate equal loading. (B) Immuno-
kinase assays indicated that CK2αWT or holo-CK2WT could phosphorylate only the wild type EEF1D-FLAG in in vitro kinase assays. Results are
representative of two independent experiments.4898 dx.doi.org/10.1021/pr2008994 |J. Proteome Res. 2011, 10, 4887–4901
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earlier ﬁndings, we performed the ﬁrst experimental studies that
conclusivelydemonstratethatEEF1DisphosphorylatedbyCK2
incells.Thisconclusionissupportedbytheobservationsthat
32P
incorporation into endogenous EEF1D is diminished in cells
treated withCK2inhibitors(Figure2) andthatEEF1D-FLAG is
directly phosphorylated by CK2 (Figure 3 7). The dramatic
increase in the in vitro phosphorylation of immuno-precipitated
EEF1D-FLAG by CK2 that is observed following λ-phosphatase
treatmentindicatesthattheCK2siteisphosphorylatedincells,a
conclusion that is reinforced through the use of a phospho-
speciﬁc antibody recognizing pS162 of EEF1D. The use of this
phospho-speciﬁcantibodytodetectadecreasedphosphorylation
ofEEF1D-FLAGincellstreatedwithCK2inhibitorsorcellswith
siRNA-mediated knockdown of CK2 further supports the con-
clusion that EEF1D is a direct physiological substrate for CK2.
Furthermore,thedemonstrationthatphosphorylationofEEF1D
in the presence of CK2 inhibitors is restored by inhibitor-
resistant forms of CK2 (Figures 5B C and 6) further suggests
thatEEF1DisabonaﬁdeCK2substrate.Giventheemergenceof
CK2 as a candidate for molecular-targeted therapy,
76,77 it could
thus be envisaged that the phosphorylation of EEF1D could be
used to validate the eﬀectiveness of CK2 inhibitor treatments in
cells or tissues.
While our studies clearly indicate that EEF1D is a bona ﬁde
physiological substrate for CK2, it is important to note that
treatment with CK2 inhibitors or siRNA-mediated knockdown
of CK2 had a relatively modest eﬀect on the levels of EEF1D
phosphorylation as detected by the phospho-speciﬁc S162 anti-
body. By comparison, there was a striking decrease in
32P
incorporation into EEF1D seen upon treatment of
32P-labeled
cellswithCK2inhibitors.Thisdiscrepancymayarisebecausethe
phosphospeciﬁc antibodies will detect total steady-state levels of
EEF1D whereas
32P labeling will only detect the population of
the EEF1D that is phosphorylated during the labeling period.
Furthermore, 2D proﬁles of transfected EEF1D-FLAG suggest
that the phosphorylation of EEF1D may occur shortly after, and
possibly coincident with, its synthesis and that once it is phos-
phorylated,thephosphorylationofS162mayberelativelystable.
Our ﬁndings are also consistent with the prospect that CK2 may
indeed be constitutively active in cells, a conclusion that would
be in keeping with structural insights and with its high speciﬁc
activity when expressed as a recombinant enzyme in bacteria.
Collectively, these results suggest that the phosphorylation of
S162 would be most useful as a marker for CK2 inhibition under
circumstances of long-term CK2 inhibition as would be the case
when CK2 inhibitors are used therapeutically.
77
Overall, many protein kinases have emerged as attractive
targets for cancer therapy, an observation that has prompted
interest in the development of many novel protein kinase inhi-
bitors with a wide range of speciﬁcities.
5,15,45,78 Given the close
similarity between many members of the protein kinase family,
the prospect for oﬀ-target eﬀects is a major concern particularly
for ATP competitive inhibitors that includes TBB and its
derivates used in our study.
15,45,78,79 Accordingly, it is imperative
that systematic and unbiased methods be available to evaluate
speciﬁcity and identify any possible side eﬀects of these com-
pounds.
15 Additionally, identiﬁcation of good biomarker candi-
dates for kinase inhibition is important for conﬁrmation that the
inhibitors eﬀectively neutralize the appropriate target in cells or
tissues.
80 Toward these goals, the strategy used here for CK2 is
not only a powerful and reliable tool for protein kinase substrate
or biomarker candidate identiﬁcation and validation, but may
alsobe easilyadapted to other protein kinases. Furthermore, this
method can be combined with other known phosphoproteomic
strategies
81,82tovalidatecandidatesubstratesforproteinkinases.
The adaptability of this strategy for inhibitor validation relies on
the availability of kinase inhibitors and information regarding
the structural basis of inhibition to enable the generation of
the inhibitor-resistant form of the kinase. It can also be readily
envisaged that this strategy could be modiﬁed to employ shRNA/
siRNA or RNAi in combination with knockdown-resistant con-
structs. Overall, it is evident that protein kinase inhibitors are
promising agents for therapy. Furthermore, the emergence of
new strategies to identify phosphorylation sites and phospho-
peptides at unprecedented rates oﬀers the promise of yielding a
comprehensive understanding of the role of protein kinases and
protein phosphorylation in cell regulation. By combining func-
tional proteomics with chemical genetics, as illustrated by the
strategy employed in this study, it is possible to capitalize on
advances in both of these areas to reveal bona ﬁde protein kinase
substrates and identify biomarkers for protein kinase inhibition.
’ASSOCIATED CONTENT
b S Supporting Information
Tables S1, S2, and Figures S1, S2, S3, S4. This material is
available free of charge via the Internet at http://pubs.acs.org.
’AUTHOR INFORMATION
Corresponding Author
*Department of Biochemistry, Schulich School of Medicine and
Dentistry,TheUniversity ofWestern Ontario,London,Ontario,
N6A 5C1, Canada. Tel: 1-519 661-4186. Fax: 1-519 661-3175.
E-mail: litchﬁ@uwo.ca.
’ACKNOWLEDGMENT
WethankDr.KenYeung,CunjieZhangandKristinaJurcicfor
their help with the MS identiﬁcation and Ashley French for her
assistance with plasmid construction. We also thank Dr. Silvia
Penuela and the members of the Litchﬁeld lab for their help
with manuscript editing. Protein separation and identiﬁcation
were performed in the MALDI/Mass Spectrometry Facility
and the Functional Proteomics Facility within the Schulich
School of Medicine and Dentistry at the University of Western
Ontario. This work was supported by the Canadian Cancer
Society Research Institute with funds from the Canadian
Cancer Society.
’REFERENCES
(1) Manning,G.;Whyte,D.B.;Martinez,R.;Hunter,T.;Sudarsanam,
S. The protein kinase complement of the human genome. Science 2002,
298, 1912–34.
(2) Johnson, S. A.; Hunter, T. Kinomics: methods for deciphering
the kinome. Nat. Methods 2005, 2 (1), 17–25.
(3) Channavajhala, P.; Seldin, D. C. Functional interaction of
protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene 2002,
21 (34), 5280–8.
(4) Kelliher,M.A.;Seldin,D.C.;Leder,P.Tal-1inducesTcellacute
lymphoblastic leukemia accelerated by casein kinase II alpha. EMBO J.
1996, 15, 5160–6.
(5) Bettayeb, K.; Tirado, O. M.; Marionneau-Lambot, S.; Ferandin,
Y.; Lozach, O.; Morris, J. C.; Mateo-Lozano, S.; Drueckes, P.;
Sch€ achtele, C.; Kubbutat, M. H.; Liger, F.; Marquet, B.; Joseph, B.;4899 dx.doi.org/10.1021/pr2008994 |J. Proteome Res. 2011, 10, 4887–4901
Journal of Proteome Research ARTICLE
Echalier,A.;Endicott,J.A.;Notario,V.;Meijer,L.Meriolins,anewclass
of cell death inducing kinase inhibitors with enhanced selectivity for
cyclin-dependent kinases. Cancer Res. 2007, 67 (17), 8325–34.
(6) Bantscheﬀ, M.;Eberhard, D.;Abraham, Y.; Bastuck, S.;Boesche,
M.;Hobson,S.;Mathieson,T.;Perrin,J.;Raida,M.;Rau,C.;Reader,V.;
Sweetman, G.; Bauer, A.; Bouwmeester, T.; Hopf, C.; Kruse, U.;
Neubauer,G.;Ramsden,N.;Rick,J.;Kuster,B.;Drewes,G.Quantitative
chemicalproteomicsrevealsmechanismsofactionofclinicalABLkinase
inhibitors. Nat. Biotechnol. 2007, 25 (9), 1035–44.
(7) Jabbour, E.; Cortes, J. E.; Ghanem, H.; O’Brien, S.; Kantarjian,
H. M. Targeted therapy in chronic myeloid leukemia. Expert Rev.
Anticancer Ther. 2008, 8 (1), 99–110.
(8) Quint  as-Cardama, A.; Kantarjian, H.; Cortes, J. Flying under the
radar: the new wave of BCR-ABL inhibitors. Nat. Rev. Drug Discovery
2007, 6 (10), 834–48.
(9) Shah, N. P.; Tran, C.; Lee, F. Y.; Chen, P.; Norris, D.; Sawyers,
C. L. Overriding imatinib resistance with a novel ABL kinase inhibitor.
Science 2004, 305 (5682), 399–401.
(10) Cozza, G.; Mazzorana, M.; Papinutto, E.; Bain, J.; Elliott, M.;
di Maira, G.; Gianoncelli, A.; Pagano, M. A.; Sarno, S.; Ruzzene, M.;
Battistutta, R.; Meggio, F.; Moro, S.; Zagotto, G.; Pinna, L. A. Quina-
lizarin as a potent, selective and cell-permeable inhibitor of protein
kinase CK2. Biochem. J. 2009, 421 (3), 387–95.
(11) Gianoncelli,A.;Cozza,G.;Orzeszko,A.;Meggio,F.;Kazimierczuk,
Z.; Pinna, L. A. Tetraiodobenzimidazoles are potent inhibitors of protein
kinase CK2. Bioorg. Med. Chem. 2009, 17 (20), 7281–9.
(12) Najda-Bernatowicz, A.; Lebska, M.; Orzeszko, A.; Kopanska,
K.;Krzywinska,E.;Muszynska,G.;Bretner,M.Synthesisofnewanalogs
of benzotriazole, benzimidazole and phthalimide-potential inhibitors of
human protein kinase CK2. Bioorg. Med. Chem. 2009, 17 (4), 1573–8.
(13) Sarno,S.;Ruzzene,M.;Frascella,P.;Pagano,M.A.;Meggio,F.;
Zambon, A.; Mazzorana, M.; Di Maira, G.; Lucchini, V.; Pinna, L. A.
Development and exploitation of CK2 inhibitors. Mol. Cell. Biochem.
2005, 274 (1 2), 69–76.
(14) Zhu, D.; Hensel, J.; Hilgraf, R.; Abbasian, M.; Pornillos, O.;
Deyanat-Yazdi, G.; Hua, X. H.; Cox, S. Inhibition of protein kinase CK2
expression and activity blocks tumor cell growth. Mol. Cell. Biochem.
2010, 333 (1 2), 159–67.
(15) Duncan, J. S.; Gyenis, L.; Lenehan, J.; Bretner, M.; Graves,
L. M.; Haystead, T. A.; Litchﬁeld, D. W. An unbiased evaluation of CK2
inhibitors by chemo-proteomics: characterization of inhibitor eﬀects on
CK2 and identiﬁcation of novel inhibitor targets. Mol. Cell. Proteomics
2008, 7 (6), 1077–88.
(16) Litchﬁeld, D. W. Protein kinase CK2: structure, regulation and
role in cellular decisions of life and death. Biochem. J. 2003, 369,1 –15.
(17) Hanks, S. K.; Hunter, T. Protein kinases 6. The eukaryotic
protein kinase superfamily: kinase (catalytic) domain structure and
classiﬁcation. FASEB J. 1995, 9 (8), 576–96.
(18) Hunter, T.; Plowman, G. D. The protein kinases of budding
yeast: six score and more. Trends Biochem. Sci. 1997, 22 (1), 18–22.
(19) Vilk, G.; Weber, J. E.; Turowec, J. P.; Duncan, J. S.; Wu, C.;
Derksen, D.R.;Zien,P.;Sarno,S.; Donella-Deana,A.;Lajoie,G.;Pinna,
L. A.; Li, S. S.; Litchﬁeld, D. W. Protein kinase CK2 catalyzes tyrosine
phosphorylation in mammalian cells. Cell Signal. 2008, 11, 1942–51.
(20) Litchﬁeld,D.W.;L€ uscher,B.CaseinkinaseIIinsignaltransduction
and cell cycle regulation. Mol. Cell. Biochem. 1993, 127 128, 187–99.
(21) St-Denis, N. A.; Derksen, D. R.; Litchﬁeld, D. W. Evidence for
regulationofmitoticprogressionthroughtemporalphosphorylationand
dephosphorylation of CK2alpha. Mol. Cell. Biol. 2009, 29 (8), 2068–81.
(22) St-Denis,N.A.;Bailey,M.L.;Parker,E.L.;Vilk,G.;Litchﬁeld,D.W.
Localization of phosphorylated CK2{alpha} to the mitotic spindle requires
the peptidyl-prolyl isomerase Pin1. J. Cell Sci. 2011, 124 (Pt 14), 2341–8.
(23) Ahmad, K. A.; Wang, G.; Unger, G.; Slaton, J.; Ahmed, K. Protein
kinase CK2 - A key suppressor of apoptosis. Adv Enzyme Regul 2008, 48,
179–87.
(24) Wang, G.; Ahmad, K. A.; Harris, N. H.; Ahmed, K. Impact of
protein kinaseCK2 oninhibitor ofapoptosis proteins in prostate cancer
cells. Mol. Cell. Biochem. 2008, 316 (1 2), 91–7.
(25) Duncan, J. S.; Turowec, J. P.; Vilk, G.; Li, S. S.; Gloor, G. B.;
Litchﬁeld, D. W. Regulation of cell proliferation and survival: Conver-
genceofproteinkinasesandcaspases.Biochim.Biophys.Acta2010,1804
(3), 505–10.
(26) Duncan, J. S.; Turowec, J. P.; Duncan, K. E.; Vilk, G.; Wu, C.;
L€ uscher, B.; Li, S. S.; Gloor, G. B.; Litchﬁeld, D. W. A Peptide-based
target screen implicates the protein kinase CK2 in the global regulation
of caspase signaling. Sci. Signal. 2011, 4 (172), ra30.
(27) Turowec, J. P.; Duncan, J. S.; Gloor, G. B.; Litchﬁeld, D. W.
Regulation of caspase pathways by protein kinase CK2: identiﬁcation of
proteins with overlapping CK2 and caspase consensus motifs. Mol. Cell.
Biochem. 2011, DOI: 10.1007/s11010-011-0972-5.
(28) Cabrejos, M. E.; Allende, C. C.; Maldonado, E. Eﬀects of
phosphorylationbyproteinkinaseCK2onthehumanbasalcomponents
of the RNA polymerase II transcription machinery. J. Cell. Biochem.
2004, 93 (1), 2–10.
(29) Tsuchiya, Y.; Akashi, M.; Matsuda, M.; Goto, K.; Miyata, Y.;
Node, K.; Nishida, E. Involvement of the protein kinase CK2 in the
regulationofmammaliancircadianrhythms.Sci.Signal.2009,2(73),ra26.
(30) Landesman-Bollag, E.; Romieu-Mourez, R.; Song, D. H.;
Sonenshein, G. E. Cardiﬀ RD; Seldin DC, Protein kinase CK2 in
mammary gland tumorigenesis. Oncogene 2001, 20 (25), 3247–57.
(31) Gyenis, L.; Litchﬁeld, D. W. The emerging CK2 interactome:
insights into the regulation and functions of CK2. Mol. Cell. Biochem.
2008, 316,5 –14.
(32) Olsten, M. E.; Weber, J. E.; Litchﬁeld, D. W. CK2 interacting
proteins: emerging paradigms for CK2 regulation? Mol. Cell. Biochem.
2005, 274 (1 2), 115–24.
(33) Meggio, F.; Pinna, L. A. One-thousand-and-one substrates of
protein kinase CK2? FASEB J. 2003, 17 (3), 349–368.
(34) Dai,J.;Jin,W.H.;Sheng,Q.H.;Shieh,C.H.;Wu,J.R.;Zeng,R.
Protein phosphorylation and expression proﬁling by Yin-yang multi-
dimensional liquid chromatography (Yin-yang MDLC) mass spectro-
metry. J. Proteome Res. 2007, 6 (1), 250–62.
(35) Gevaert, K.; Staes, A.; Van Damme, J.; De Groot, S.; Hugelier,
K.; Demol, H.; Martens, L.; Goethals, M.; Vandekerckhove, J. Global
phosphoproteome analysis on human HepG2 hepatocytes using
reversed-phase diagonal LC. Proteomics 2005, 5 (14), 3589–99.
(36) Olsen, J. V.; Blagoev, B.; Gnad, F.; Macek, B.; Kumar, C.;
Mortensen, P.; Mann, M. Global, in vivo, and site-speciﬁc phosphoryla-
tion dynamics in signaling networks. Cell 2006, 127 (3), 635–48.
(37) Olsen, J. V.; Vermeulen, M.; Santamaria, A.; Kumar, C.; Miller,
M. L.; Jensen, L. J.; Gnad, F.; Cox, J.; Jensen, T. S.; Nigg, E. A.; Brunak,
S.; Mann, M. Quantitative phosphoproteomics reveals widespread full
phosphorylation site occupancy during mitosis. Sci. Signal. 2010, 3
(104), ra3.
(38) Salvi, M.; Sarno, S.; Cesaro, L.; Nakamura, H.; Pinna, L. A.
ExtraordinarypleiotropyofproteinkinaseCK2revealedbyweblogo
phosphoproteome analysis. Biochim. Biophys. Acta 2009, 1793 (5),
847–59.
(39) Yoo,P.D.;Ho,Y.S.;Zhou,B.B.;Zomaya,A.Y.SiteSeek:Post-
translational modiﬁcation analysis using adaptive locality-eﬀective kernel
methods and new proﬁles. BMC Bioinform. 2008, 9 (1), 272.
(40) Zien, P.; Duncan, J. S.; Skierski, J.; Bretner, M.; Litchﬁeld,
D. W.; Shugar, D. Tetrabromobenzotriazole (TBBt) and tetrabromo-
benzimidazole (TBBz) as selective inhibitors of protein kinase CK2:
evaluation of their eﬀects on cells and diﬀerent molecular forms of
human CK2. Biochim. Biophys. Acta 2005, 1754 (1 2), 271–80.
(41) Duncan, J. S.; Litchﬁeld, D. W. Too much of a good thing: the
role of protein kinase CK2 in tumorigenesis and prospects for ther-
apeuticinhibitionofCK2.Biochim.Biophys.Acta2008,1784(1),33–47.
(42) Sarno,S.;Ghisellini,P.;Pinna,L.A.Uniqueactivationmechan-
ism of protein kinase CK2. The N-terminal segment is essential for
constitutive activity of the catalytic subunit but not of the holoenzyme.
J. Biol. Chem. 2002, 277 (25), 22509–14.
(43) French, A. C.; Luscher, B.; Litchﬁeld, D. W. Development of a
stabilized form of the regulatory CK2beta subunit that inhibits cell
proliferation. J. Biol. Chem. 2007, 282 (40), 29667–77.4900 dx.doi.org/10.1021/pr2008994 |J. Proteome Res. 2011, 10, 4887–4901
Journal of Proteome Research ARTICLE
(44) Zhang, C.; Vilk, G.; Canton, D. A.; Litchﬁeld, D. W. Phosphor-
ylationregulatesthestabilityoftheregulatoryCK2betasubunit.Oncogene
2002, 21 (23), 3754–64.
(45) Pagano, M. A.; Bain, J.; Kazimierczuk, Z.; Sarno, S.; Ruzzene,
M.;DiMaira,G.;Elliott,M.;Orzeszko,A.;Cozza,G.;Meggio,F.;Pinna,
L. A. The selectivity of inhibitors of protein kinase CK2: an update.
Biochem. J. 2008, 415 (3), 353–65.
(46) Mazzorana, M.; Pinna, L. A.; Battistutta, R. A structural insight
into CK2 inhibition. Mol. Cell. Biochem. 2008, 316 (1 2), 57–62.
(47) Nieﬁnd,K.;Guerra,B.;Pinna,L.A.;Issinger,O.G.;Schomburg,
D. Crystal structure of the catalytic subunit of protein kinase CK2 from
Zea mays at 2.1 A resolution. EMBO J. 1998, 17 (9), 2451–62.
(48) Nieﬁnd, K.; P€ utter, M.; Guerra, B.; Issinger, O. G.; Schomburg,
D. GTP plus water mimic ATP in the active site of protein kinase CK2.
Nat. Struct. Biol. 1999, 6 (12), 1100–3.
(49) Zhang, N.; Zhong, R. Structural basis for decreased aﬃnity of
Emodin binding to Val66-mutated human CK2alpha as determined by
molecular dynamics. J. Mol. Model. 2010, 16 (4), 771–80.
(50) Roberts,E.C.;Hammond,K.;Traish,A.M.;Resing,K.A.;Ahn,
N. G. Identiﬁcation of G2/M targets for the MAP kinase pathway by
functional proteomics. Proteomics 2006, 6 (16), 4541–53.
(51) De Bortoli, M.; Castellino, R. C.; Lu, X. Y.; Deyo, J.; Sturla,
L.M.;Adesina,A.M.;Perlaky,L.;Pomeroy,S.L.;Lau,C.C.;Man,T.K.;
Rao, P. H.; Kim, J. Y. Medulloblastoma outcome is adversely associated
with overexpression of EEF1D, RPL30, and RPS20 on the long arm of
chromosome 8. BMC Cancer 2006, 6, 223.
(52) Ogawa,K.;Utsunomiya,T.;Mimori,K.;Tanaka,Y.;Tanaka,F.;
Inoue, H.; Murayama, S.; Mori, M. Clinical signiﬁcance of elongation
factor-1 delta mRNA expression in oesophageal carcinoma. Br. J. Cancer
2004, 91 (2), 282–6.
(53) Gnad, F.; Ren, S.; Cox, J.; Olsen, J. V.; Macek, B.; Oroshi, M.;
Mann, M. PHOSIDA (phosphorylation site database): management,
structural and evolutionary investigation, and prediction of phospho-
sites. Genome Biol. 2007, 8 (11), R250.
(54) Sambrook, J.; Fritsch, E. F.; Maniatis, T. Molecular Cloning: A
Laboroatory Manual, 2nd ed.; Cold Spring Harbor Laboratory: Cold
Spring Harbor, NY, 1989.
(55) Penner, C. G.; Wang, Z.; Litchﬁeld, D. W. Expression and
localizationofepitope-taggedproteinkinaseCK2.J.Cell.Biochem.1997,
64 (4), 525–37.
(56) Reed, S. E.; Staley, E. M.; Mayginnes, J. P.; Pintel, D. J.; Tullis,
G.E.Transfectionofmammaliancellsusinglinearpolyethylenimineisa
simple and eﬀective means of producing recombinant adeno-associated
virus vectors. J Virol. Methods 2006, 138 (1 2), 85–98.
(57) Towbin, H.; Staehelin, T.; Gordon, J. Electrophoretic transfer
of proteins from polyacrylamide gels to nitrocellulose sheets: procedure
and some applications. Proc Natl Acad Sci U S A 1979, 76 (9), 4350–4.
(58) Litchﬁeld,D.W.;Lozeman,F.J.;Cicirelli,M.F.;Harrylock,M.;
Ericsson, L. H.; Piening, C. J.; Krebs, E. G. Phosphorylation of the beta
subunit of casein kinase II in human A431 cells. Identiﬁcation of the
autophosphorylation site and a site phosphorylated by p34cdc2. J. Biol.
Chem. 1991, 266 (30), 20380–9.
(59) Litchﬁeld, D. W.; L€ uscher, B.; Lozeman, F. J.; Eisenman, R. N.;
Krebs, E. G. Phosphorylation of casein kinase II by p34cdc2 in vitro and
at mitosis. J. Biol. Chem. 1992, 267 (20), 13943–51.
(60) Vilk, G.; Saulnier, R. B.; Pierre, R., St; Litchﬁeld, D. W.
Inducible expression of protein kinase CK2 in mammalian cells.
Evidence for functional specialization of CK2 isoforms. J. Biol. Chem.
1999, 274 (20), 14406–14.
(61) Bosc, D. G.; Slominski, E.; Sichler, C.; Litchﬁeld, D. W. Phos-
phorylation ofcasein kinase IIby p34cdc2. Identiﬁcationofphosphoryla-
tion sites using phosphorylation site mutants in vitro. J. Biol. Chem. 1995,
270 (43), 25872–8.
(62) Turowec, J. P.; Duncan, J. S.; French, A. C.; Gyenis, L.; Denis,
N.A.,St;Vilk,G.;Litchﬁeld,D.W.ProteinkinaseCK2isaconstitutively
active enzyme that promotes cell survival: strategies to identify CK2
substrates and manipulate its activity in mammalian cells. Methods
Enzymol. 2010, 484, 471–93.
(63) Bosc, D. G.; Graham, K. C.; Saulnier, R. B.; Zhang, C.; Prober,
D . ;G i e t z ,R .D . ;L i t c h ﬁeld, D. W. Identiﬁcation and characterization of
CKIP-1, a novel pleckstrin homology domain-containing protein that
interactswithproteinkinaseCK2.J.Biol.Chem.2000,275(19),14295–306.
(64) Litchﬁeld, D. W.; Lozeman, F. J.; Piening, C.; Sommercorn, J.;
Takio,K.;Walsh,K.A.;Krebs,E.G.SubunitstructureofcaseinkinaseII
frombovinetestis. Demonstrationthatthealphaandalpha’subunitsare
distinct polypeptides. J. Biol. Chem. 1990, 265 (13), 7638–44.
(65) Rigbolt, K. T.; Prokhorova, T. A.; Akimov, V.; Henningsen, J.;
Johansen, P. T.; Kratchmarova, I.; Kassem, M.; Mann, M.; Olsen, J. V.;
Blagoev, B. System-wide temporal characterization of the proteome and
phosphoproteome of human embryonic stem cell diﬀerentiation. Sci.
Signal. 2011, 4 (164), rs3.
(66) Keenan, J.; Murphy, L.; Henry, M.; Meleady, P.; Clynes, M.
Proteomic analysis of multidrug-resistance mechanisms in adriamycin-
resistant variants of DLKP, a squamous lung cancer cell line. Proteomics
2009, 9 (6), 1556–66.
(67) Yang, S.; Du, J.; Wang, Z.; Yuan, W.; Qiao, Y.; Zhang, M.;
Zhang, J.; Gao, S.; Yin, J.; Sun, B.; Zhu, T. BMP-6 promotes E-cadherin
expression through repressing deltaEF1 in breast cancer cells. BMC
Cancer 2007, 7, 211.
(68) Wain, L. V.; Pedroso, I.; Landers, J. E.; Breen, G.; Shaw, C. E.;
Leigh,P.N.;Brown,R.H.;Tobin,M.D.;Al-Chalabi,ATheroleofcopy
number variation in susceptibility to amyotrophic lateral sclerosis:
genome-wide association study and comparison with published loci.
PLoS One 2009, 4 (12), e8175.
(69) Riis, B.; Rattan, S. I.; Clark, B. F.; Merrick, W. C. Eukaryotic
protein elongation factors. Trends Biochem. Sci. 1990, 15 (11), 420–4.
(70) Sivan, G.; Aviner, R.; Elroy-Stein, O. Mitotic modulation of
translation elongation factor 1 leads to hindered tRNA delivery to
ribosomes. J. Biol. Chem. 2011, 286 (32), 27927–35.
(71) Palen, E.; Venema, R. C.; Chang, Y. W.; Traugh, J. A. GDP as a
regulator of phosphorylation of elongation factor 1 by casein kinase II.
Biochemistry 1994, 33 (28), 8515–20.
(72) Sheu,G.T.;Traugh,J.A.Recombinantsubunitsofmammalian
elongation factor 1 expressed in Escherichia coli. Subunit interactions,
elongation activity, and phosphorylation by protein kinase CKII. J. Biol.
Chem. 1997, 272 (52), 33290–7.
(73) Sheu, G. T.; Traugh, J. A. A structural model for elongation
factor 1 (EF-1) and phosphorylation by protein kinase CKII. Mol. Cell.
Biochem. 1999, 191 (1), 181–6.
(74) Linding, R.; Jensen, L. J.; Ostheimer, G. J.; van Vugt, M. A.;
Jørgensen, C.; Miron, I. M.; Diella, F.; Colwill, K.; Taylor, L.; Elder, K.;
Metalnikov, P.; Nguyen, V.; Pasculescu, A.; Jin, J.; Park, J. G.; Samson,
L. D.; Woodgett, J. R.; Russell, R. B.; Bork, P.; Yaﬀe, M. B.; Pawson, T.
Systematic discovery of in vivo phosphorylation networks. Cell 2007,
129 (7), 1415–26.
(75) Linding,R.;Jensen,L.J.;Pasculescu,A.;Olhovsky,M.;Colwill,
K.; Bork, P.; Yaﬀe, M. B.; Pawson, T. NetworKIN: a resource for
exploring cellular phosphorylation networks. Nucleic Acids Res. 2008, 36
(Database issue), D695–9.
(76) Perez, D.I.;Gil, C.;Martinez,A.Protein kinases CK1andCK2
asnewtargetsforneurodegenerativediseases.MedResRev2010inpress.
(77) Pierre, F.; Chua, P. C.; O’Brien, S. E.; Siddiqui-Jain, A.;
Bourbon, P.; Haddach, M.; Michaux, J.; Nagasawa, J.; Schwaebe,
M. K.; Stefan, E.; Vialettes, A.; Whitten, J. P.; Chen, T. K.; Darjania,
L.;Stansﬁeld,R.;Bliesath,J.;Drygin,D.;Ho,C.;Omori,M.;Proﬃtt,C.;
S t r e i n e r ,N . ;R i c e ,W .G . ;R y c k m a n ,D .M . ;A n d e r e s ,K .P r e - c l i n i c a l
characterizationofCX-4945,apotentandselectivesmallmoleculeinhibitor
ofCK2forthetreatmentofcancer.Mol.Cell.Biochem.2011,DOI:10.1007/
s11010-011-0956-5.
(78) Schneider,C.C.;Hessenauer,A.;Montenarh,M.;G€ otz,C.p53
is dispensable for the induction of apoptosis after inhibition of protein
kinase CK2. Prostate 2010, 70 (2), 126–34.
(79) Zien, P.; Bretner, M.; Zastapilo, K.; Szyszka, R.; Shugar, D.
Selectivity of 4,5,6,7-tetrabromobenzimidazole as an ATP-competitive
potent inhibitor of protein kinase CK2 from various sources. Biochem.
Biophys. Res. Commun. 2003, 306 (1), 129–33.4901 dx.doi.org/10.1021/pr2008994 |J. Proteome Res. 2011, 10, 4887–4901
Journal of Proteome Research ARTICLE
(80) Mizuarai, S.; Yamanaka, K.; Itadani, H.; Arai, T.; Nishibata, T.;
Hirai, H.; Kotani, H. Discovery of gene expression-based pharmacody-
namic biomarker for a p53 context-speciﬁc anti-tumor drug Wee1
inhibitor. Mol. Cancer 2009, 8, 34.
(81) Morandell, S.; Stasyk, T.; Grosstessner-Hain, K.; Roitinger, E.;
Mechtler, K.; Bonn, G. K.; Huber, L. A. Phosphoproteomics strategies
for the functional analysis of signal transduction. Proteomics 2006, 6
(14), 4047–56.
(82) Thingholm, T. E.; Jensen, O. N.; Larsen, M. R. Analytical
strategies for phosphoproteomics. Proteomics 2009, 9 (6), 1451–68.